BIOQUAL Presents Financial Results for Fiscal Year 2021 and Declares Dividend

BIOQUAL Presents Financial Results for Fiscal Year 2021 and Declares Dividend




BIOQUAL Presents Financial Results for Fiscal Year 2021 and Declares Dividend

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC-Pink:BIOQ) ( www.bioqual.com):

 

 

 

 

2021

 

 

2020

Revenue

 

$

57,683,502

 

$

46,360,201

     

Income Before Income Tax

 

$

8,616,025

 

$

5,488,938

     

Net Income

 

$

6,326,825

 

$

4,230,938

     

Basic Earnings per Share

   

of Common Stock

 

$

7.08

 

$

4.74

     

Diluted Earnings per Share

   

of Common Stock

 

$

7.08

 

$

4.73

     

Weighted Average

     

Number of Shares Outstanding

     

For Basic Per Share

 

 

894,054

 

 

 893,416

     

Weighted Average

     

Number of Shares Outstanding

     

For Diluted Earnings Per Share

 

 

894,054

 

 

893,971

BIOQUAL’s Board of Directors has declared a dividend of $1.25 per share for shareholders of record on September 29, 2021, payable on October 20, 2021. This is the twentieth dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)